Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTERCC: Folic acid vs placebo for mucositis in metastatic renal cell carcinoma
2024-515413-18-00Phase 2Completed
- Sponsor
- Central Denmark Region
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in metastatic renal cell carcinoma (mRCC) comparing Folic acid with Placebo (2 arms). Primary endpoint: CTCAE mucositis severity. Started Sep 2024; status: completed.
02
Drugs
folic acid
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2024-515413-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515413-18-00.